ColesAJTwymanCLArnoldDL, et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: A randomised controlled phase 3 trial. Lancet2012; 380: 1829–1839.
2.
Hill-CawthorneGAButtonTTuohyO, et al. Long term lymphocyte reconstitution after alemtuzumab treatment of multiple sclerosis. J Neurol Neurosurg Psychiatry2012; 83(3): 298–304.
PenkertHDelbridgeCWantiaN, et al. Fulminant central nervous system nocardiosis in a patient treated with alemtuzumab for relapsing-remitting multiple sclerosis. JAMA Neurol2016; 73(6): 757–759.
5.
ClericoMDe MercantiSArtusiCA, et al. Active CMV infection in two patients with multiple sclerosis treated with alemtuzumab. Mult Scler2017; 23(6): 874–876.
6.
HolmoyTvon der LippeHLeegaardTM.Listeria monocytogenes infection associated with alemtuzumab—A case for better preventive strategies. BMC Neurol2017; 17(1): 65.
7.
De PauwBWalshTJDonnellyJP, et al. Revised definitions of invasive fungal disease from the European Organization for Research and Treatment of Cancer/Invasive Fungal Infections Cooperative Group and the National Institute of Allergy and Infectious Diseases Mycoses Study Group (EORTC/MSG) Consensus Group. Clin Infect Dis2008; 46(12): 1813–1821.
8.
MartinSIMartyFMFiumaraK, et al. Infectious complications associated with alemtuzumab use for lymphoproliferative disorders. Clin Infect Dis2006; 43(1): 16–24.
9.
GaitanMIYsrraelitMCCorrealeJ.Neutropenia in patients with multiple sclerosis treated with alemtuzumab. JAMA Neurol2017; 74(9): 1143–1144.
10.
BuonomoARZappuloEViceconteG, et al. Risk of opportunistic infections in patients treated with alemtuzumab for multiple sclerosis. Expert Opin Drug Saf2018; 17(7): 709–717.
